These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 38453159)

  • 1. Carboplatin in Patients With Metastatic Castration-Resistant Prostate Cancer Harboring Somatic or Germline Homologous Recombination Repair Gene Mutations: Phase II Single-Arm Trial.
    Jain R; Kumar A; Sharma A; Sahoo RK; Sharma A; Seth A; Nayak B; Shamim SA; Kaushal S; Kp H; Das CJ; Batra A
    JMIR Res Protoc; 2024 Apr; 13():e54086. PubMed ID: 38453159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carboplatin in metastatic castration-resistant prostate cancer patients with molecular alterations of the DNA damage repair pathway: the PRO-CARBO phase II trial.
    Coquan E; Penel N; Lequesne J; Leman R; Lavaud P; Neviere Z; Brachet PE; Meriaux E; Carnot A; Boutrois J; Castera M; Goardon N; Muller E; Leconte A; Thiery-Vuillemin A; Clarisse B; Joly F
    Ther Adv Urol; 2024; 16():17562872241229876. PubMed ID: 38425504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
    de Bono JS; Mehra N; Scagliotti GV; Castro E; Dorff T; Stirling A; Stenzl A; Fleming MT; Higano CS; Saad F; Buttigliero C; van Oort IM; Laird AD; Mata M; Chen HC; Healy CG; Czibere A; Fizazi K
    Lancet Oncol; 2021 Sep; 22(9):1250-1264. PubMed ID: 34388386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Clarke N; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Goessl C; Burgents J; Kozarski R; Hodgson D; Learoyd M; Saad F
    Lancet Oncol; 2018 Jul; 19(7):975-986. PubMed ID: 29880291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating "BRCAness" Genotype (ROAR).
    Sahu KK; Li H; Mathew Thomas V; Benson M; Boucher K; Gupta S; Kohli M; Swami U; Agarwal N; Maughan BL
    Oncologist; 2024 May; 29(5):450-e725. PubMed ID: 38452035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA-Damage-Repair Gene Alterations in Genitourinary Malignancies.
    Dariane C; Timsit MO
    Eur Surg Res; 2022; 63(4):155-164. PubMed ID: 35944490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
    Antonarakis ES; Gomella LG; Petrylak DP
    Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes.
    Olmos D; Lorente D; Alameda D; Cattrini C; Romero-Laorden N; Lozano R; Lopez-Casas PP; Jambrina A; Capone C; Vanden Broecke AM; Trevisan M; Van Sanden S; Jürgens A; Herrera-Imbroda B; Castro E
    Ann Oncol; 2024 May; 35(5):458-472. PubMed ID: 38417742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1.
    Saad F; de Bono J; Barthélémy P; Dorff T; Mehra N; Scagliotti G; Stirling A; Machiels JP; Renard V; Maruzzo M; Higano CS; Gurney H; Healy C; Bhattacharyya H; Arondekar B; Niyazov A; Fizazi K
    Eur Urol; 2023 Apr; 83(4):352-360. PubMed ID: 35750582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging Role of PARP Inhibitors in Metastatic Prostate Cancer.
    Unlu S; Kim JW
    Curr Oncol Rep; 2022 Nov; 24(11):1619-1631. PubMed ID: 35931885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poly (ADP-ribose) Polymerase Inhibitors Have Comparable Efficacy with Platinum Chemotherapy in Patients with BRCA-positive Metastatic Castration-resistant Prostate Cancer. A Systematic Review and Meta-analysis.
    Fazekas T; Széles ÁD; Teutsch B; Csizmarik A; Vékony B; Kói T; Ács N; Hegyi P; Hadaschik B; Nyirády P; Szarvas T
    Eur Urol Oncol; 2024 Jun; 7(3):365-375. PubMed ID: 37722977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer.
    Adashek JJ; Jain RK; Zhang J
    Cells; 2019 Aug; 8(8):. PubMed ID: 31404966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial.
    Fizazi K; Retz M; Petrylak DP; Goh JC; Perez-Gracia J; Lacombe L; Zschäbitz S; Burotto M; Mahammedi H; Gravis G; Bastos DA; McCune SL; Vázquez Limón JC; Kwan EM; Castellano D; Fléchon A; Saad F; Grimm MO; Shaffer DR; Armstrong AJ; Bhagavatheeswaran P; Amin NP; Ünsal-Kaçmaz K; Wang X; Li J; Loehr A; Pachynski RK
    J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 35977756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct Response to Platinum-Based Chemotherapy among Patients with Metastatic Castration-Resistant Prostate Cancer Harboring Alterations in Genes Involved in Homologous Recombination.
    Fan L; Fei X; Zhu Y; Chi C; Pan J; Sha J; Xin Z; Gong Y; Du X; Wang Y; Dong B; Xue W
    J Urol; 2021 Sep; 206(3):630-637. PubMed ID: 33904759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer.
    Carr TH; Adelman C; Barnicle A; Kozarewa I; Luke S; Lai Z; Hollis S; Dougherty B; Harrington EA; Kang J; Saad F; Sala N; Thiery-Vuillemin A; Clarke NW; Hodgson D; Barrett JC
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations.
    Karzai F; VanderWeele D; Madan RA; Owens H; Cordes LM; Hankin A; Couvillon A; Nichols E; Bilusic M; Beshiri ML; Kelly K; Krishnasamy V; Lee S; Lee MJ; Yuno A; Trepel JB; Merino MJ; Dittamore R; Marté J; Donahue RN; Schlom J; Killian KJ; Meltzer PS; Steinberg SM; Gulley JL; Lee JM; Dahut WL
    J Immunother Cancer; 2018 Dec; 6(1):141. PubMed ID: 30514390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic testing for homologous recombination repair (HRR) in metastatic castration-resistant prostate cancer (mCRPC): challenges and solutions.
    Scott RJ; Mehta A; Macedo GS; Borisov PS; Kanesvaran R; El Metnawy W
    Oncotarget; 2021 Aug; 12(16):1600-1614. PubMed ID: 34381565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.
    Agarwal N; Azad AA; Carles J; Fay AP; Matsubara N; Heinrich D; Szczylik C; De Giorgi U; Young Joung J; Fong PCC; Voog E; Jones RJ; Shore ND; Dunshee C; Zschäbitz S; Oldenburg J; Lin X; Healy CG; Di Santo N; Zohren F; Fizazi K
    Lancet; 2023 Jul; 402(10398):291-303. PubMed ID: 37285865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRIUMPH: phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline homologous recombination repair gene mutations.
    Markowski MC; Sternberg CN; Wang H; Wang T; Linville L; Marshall CH; Sullivan R; King S; Lotan TL; Antonarakis ES
    Oncologist; 2024 Sep; 29(9):794-800. PubMed ID: 38885246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of Rucaparib in the Treatment of Prostate Cancer: Clinical Perspectives and Considerations.
    Wu MS; Goldberg H
    Cancer Manag Res; 2022; 14():3159-3174. PubMed ID: 36411744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.